Ascletis Pharma (SEHK:1672) Following FDA Clearance Looks About Right At 3.8x P B

Ascletis Pharma (SEHK:1672) has kicked off a U.S. Phase I trial for its oral obesity candidate ASC36 after securing FDA Investigational New Drug clearance, bringing fresh attention to this Hong Kong biotech’s pipeline.

Investors have reacted cautiously in the short term, with the share price down 10.43% over the past month and 17.97% year to date. Ascletis Pharma still carries a very large 3 year total shareholder return and a 5 year total shareholder return above 200%, which suggests that traders are reassessing risk even as longer term holders remain well ahead after a period that also included wider losses reported for the first half of 2026.

Spot new biotech stories at a similar stage to Ascletis Pharma by scanning our hand picked list of 618 high quality undiscovered gems before this part of the market gets crowded.

The recent pullback in Ascletis Pharma looks caught between concern over deeper first half losses and renewed interest in its obesity pipeline. Is this valuation now tracking business reality, or is it simply reflecting sentiment whiplash?

Preferred price to book of 3.8x: Is it justified?

Valuation on Ascletis Pharma currently hinges on its P/B ratio of 3.8x, which screens as cheap against peers yet slightly expensive versus the broader Hong Kong biotechs sector, so the HK$9.45 share price sits in a tricky middle ground.

P/B compares the market value of the equity to its book value, which can be especially useful for a loss making biotech where earnings based metrics like P/E do not work well. For a research heavy group such as Ascletis Pharma, this kind of measure often reflects how much investors are willing to pay today for a pipeline that is still some distance from profitability.

Against companies with a similar focus, the stock looks inexpensive. The peer average P/B sits at a very high 78.1x, which suggests the market is paying a much richer multiple elsewhere for early stage assets, while assigning a far lower ratio to Ascletis Pharma despite its forecast 142.3% annual revenue growth and a management team with more than seven years of average tenure.

Compared with the wider Hong Kong biotechs industry, the picture flips. The sector average P/B is 3.6x, which means Ascletis Pharma trades on a slightly higher multiple even though it remains loss making and is not expected to reach profitability within the next three years. That combination of a premium to the sector average, limited revenue today at CN¥947K, and ongoing losses of CN¥591.6m suggests the market is already building in a fair amount of optimism around the obesity and antiviral franchises at the current valuation.

See what the numbers say about this price — find out in our valuation breakdown.

Result: Price-to-book of 3.8x (ABOUT RIGHT)

Still, the widened first half loss of CN¥591.6m and limited CN¥947K revenue leave Ascletis Pharma highly dependent on successful execution across a crowded obesity field.

Find out about the key risks to this Ascletis Pharma narrative.

Next Steps

Mixed signals around Ascletis Pharma can easily sway opinion, so it may be helpful to act promptly, review the underlying figures, and weigh the 1 key reward and 2 important warning signs.

Looking for more ideas beyond Ascletis Pharma?

You have seen how tricky a single biotech like Ascletis Pharma can be. Now broaden your watchlist with a few focused stock idea shortlists that many investors overlook.

This article by Simply Wall St is general in nature. We provide commentary based on historical data
and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your
financial situation. We aim to bring you long-term focused analysis driven by fundamental data.
Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material.
Simply Wall St has no position in any stocks mentioned.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com